A carregar...

Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma

BACKGROUND: Metabolic toxicities of mTOR inhibitors (mTORi) are well characterized. The purpose of the study was to investigate the relationship between these metabolic toxicities and mTORi efficacy. METHODS: From 2007 to 2011, metabolic toxicities were retrospectively collected in patients treated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Jebali, M., Elaidi, R., Brizard, M., Fouque, J., Takouchop, C., Sabatier, B., Oudard, S., Medioni, J.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5217652/
https://ncbi.nlm.nih.gov/pubmed/28061764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2993-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!